This study is looking at how well Narrowband Ultraviolet-B (UVB) phototherapy works for people with moderate to severe plaque psoriasis. Psoriasis is a skin condition that causes red, scaly patches. You might be able to join if you are an adult aged 18 or older and have had chronic plaque-type psoriasis for at least 6 months, with a certain level of severity (BSA ≥10 PASI ≥12 IGA ≥3). The study will measure success by looking at your Psoriasis Area Severity Index (PASI) score after 12 weeks of treatment. The current status of this study is unclear.

Study design

This is an open-label pilot study, meaning both you and the study team will know what treatment you are receiving. It involves 30 participants and does not specify a phase.

What's involved

You will receive Narrowband UVB phototherapy three times a week for 12 weeks. After this, you will have evaluations every 6 weeks through week 36.

Compensation

Not stated in the trial record.

Follow-up

Participants will be evaluated through week 36 to see how well the treatment response is maintained after the initial 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.